Answer
Mylotarg (gemtuzumab ozogamicin) must not be used during pregnancy unless the potential maternal benefit outweighs potential foetal risks; pregnant patients, patients becoming pregnant during treatment, and treated male partners of pregnant women must be informed of the potential foetal hazard.
Sources for this answer
- MYLOTARG 5mg powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 13Document updated
Sources checked